• logo


Every pregnant woman undergoes several blood tests during her pregnancy, which is an obstacle for hourly workers and underserved communities with limited access to healthcare. No-show rates for pregnancies of unknown location (PULs), including ectopic pregnancies, at Penn Medicine Dickens Clinic are about 25% alone; these women need remote quantitative tracking of beta-hCG. In 2023, urine-based pregnancy monitoring devices will influence 1.65 billion women worldwide. Serum-based tests are still the standard of care; community outreach programs are an existing solution, but these do not address fundamental issues with access to diagnostic centers.

Proposed Healthcare Solution

Urine-based device that replaces blood tests needed during pregnancy

Development Stage

Prototype Development

Funding Cycle



Ankita Brahmaroutu, MD
Department of Neurology

Efe Cudjoe, MD
Department of Obstetrics and Gynecology

Pranay Nadella, 
Perelman School of Medicine

Suri Brahmaroutu

Ashrita Brahmaroutu



For more information on this technology, please contact Penn Center for Innovation at pciinfo@pci.upenn.edu